COVID-19 boosters increase protection against death from the Omicron variant to 95% in people aged 50 or over, the UK Health Security Agency said on Thursday.
The UKHSA said that around six months after a second dose of any of the COVID-19 vaccines, protection against death with Omicron was around 60% in those aged 50 and over. However, this increased to around 95% two weeks after receiving a booster vaccine dose.
UKHSA added that data continued to show high levels of protection against hospitalisation from the booster. Effectiveness against hospitalisation was around 90% for the Pfizer-BioNTech shotRegister now for FREE unlimited access to Reuters.
The UKHSA also issued an initial analysis of vaccine effectiveness against the Omicron sublineage called BA.2, which is growing in Britain and Denmark, finding a similar level of protection against symptomatic disease. "After two doses effectiveness was 9% and 13% respectively for BA.1 and BA.2, after 25+ weeks," the UKHSA said. "This increased to 63% for BA.1 and 70% for BA.2 from two weeks following a booster vaccine."Reporting by Alistair Smout; Editing by Kate Holton/Guy FaulconbridgeSubscribe to our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Moderna starts trial of an omicron-specific COVID-19 vaccineBoosters of the original still protect against omicron.
Weiterlesen »
Moderna begins testing omicron-specific COVID-19 vaccine in adultsIt’s not clear whether global health authorities will order a change to the vaccine recipe in the wake of the hugely contagious omicron variant, since the original vaccines still offer good protection.
Weiterlesen »
Moderna Booster May Wane After 6 Months, Company SaysThe Moderna vaccine and booster don't protect against Omicron as well as they do against the original SARS-CoV-2
Weiterlesen »
Moderna starts trial on omicron-specific Covid booster in adultsModerna starts its clinical trial using an omicron-specific booster vaccine. Pfizer has also started testing a vaccine for omicron.
Weiterlesen »
Moderna starts clinical trial of booster shot targeting omicron Covid variantThe first participant in the trial has already received a dose of the omicron-specific booster shot, according to Moderna.
Weiterlesen »